Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. (Q43444262)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Masashi Narazaki

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Y Hishitani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Y Shima

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

T Hirano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

K Ebina

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Y Kunugiza

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

K Shi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

K Hagihara

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

T Tomita

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

H Yoshikawa

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

T Tanaka

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

A Kumanogoh

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

7 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

Scandinavian Journal of Rheumatology

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

253-259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

The Japanese experience with biologic therapies for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Immunotherapeutic implication of IL-6 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2012.762037

10.3109/03009742.2012.762037

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23470089%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference